AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Regulation FD Disclosure
On September 25, 2019, Dr. Michael Thorpy, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Clinical Neurology at Albert Einstein College of Medicine, will provide an oral presentation relating to the pharmacokinetic (PK) data derived from four Phase 1 studies of the once-nightly sodium oxybate product, FT218, being developed by Avadel Pharmaceuticals plc. A copy of the slide presentation to be used in the presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information responsive to Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.
|99.1||Slide Presentation dated September 25, 2019|
AVADEL PHARMACEUTICALS PLC Exhibit
EX-99.1 2 tv530025_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 The Pharmacokinetics of once – nightly controlled – release sodium oxybate (FT218): Overview of results from four Phase 1 Studies Dr. Michael Thorpy Director of the Sleep – Wake Disorders Center at the Montefiore Medical Center 1 Safe Harbor 2 This presentation may include forward – looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . The words “will,…
To view the full exhibit click